IgA Nephropathy

Comprehensive Clinical Guide: IgA Nephropathy (Berger’s Disease)

IgA Nephropathy (IgAN), historically referred to as Berger’s Disease, represents the most prevalent form of primary glomerulonephritis globally. It is an autoimmune-mediated renal disorder characterized by the deposition of galactose-deficient IgA1 (Gd-IgA1) immune complexes within the glomerular mesangium. This guide serves as an authoritative clinical reference for practitioners, outlining the pathophysiological mechanisms, diagnostic pathways, and long-term management strategies.

1. Clinical Definition and Overview

IgA Nephropathy is defined by the presence of predominant IgA deposits in the glomerular mesangium, often accompanied by mesangial proliferation and matrix expansion. While it can present at any age, it is most frequently diagnosed in the second and third decades of life. The clinical spectrum is highly heterogeneous, ranging from asymptomatic microscopic hematuria to rapidly progressive glomerulonephritis (RPGN) and end-stage renal disease (ESRD).

Epidemiological Significance

• Prevalence: It is the most common primary glomerulonephritis worldwide, particularly in East Asian populations.
• Gender Predisposition: A male-to-female ratio of approximately 2:1 to 3:1 is observed.
• Clinical Course: Approximately 20–40% of patients develop ESRD within 20 years of initial diagnosis.

2. Pathophysiology: The Multi-Hit Hypothesis

The current consensus on IgAN pathogenesis is described by the "four-hit hypothesis," which explains why IgA deposits form and subsequently trigger glomerular injury.

Cellular Response

Once deposited, the immune complexes activate the mesangial cells to produce pro-inflammatory cytokines (IL-6, TGF-β) and chemokines. This leads to the recruitment of monocytes/macrophages, mesangial expansion, and eventual glomerular sclerosis and tubulointerstitial fibrosis.

3. Clinical Staging and Grading (The Oxford Classification)

The Oxford Classification (MEST-C score) is the gold standard for predicting renal outcomes. It provides a standardized method for reporting renal biopsy findings.

MEST-C Scoring Criteria

• M (Mesangial hypercellularity): M0 (≤50% of glomeruli), M1 (>50%).
• E (Endocapillary hypercellularity): E0 (absent), E1 (present).
• S (Segmental glomerulosclerosis): S0 (absent), S1 (present).
• T (Tubular atrophy/interstitial fibrosis): T0 (≤25%), T1 (26-50%), T2 (>50%).
• C (Crescents): C0 (absent), C1 (≤25% of glomeruli), C2 (>25%).

4. Standard Clinical Presentation

Patients often present with clinical markers that necessitate further investigation. Key presentations include:

1. Macrohematuria: Often occurring 1–2 days following an upper respiratory tract infection ("synpharyngitic hematuria").
2. Asymptomatic Microhematuria: Frequently detected during routine school or occupational physical exams.
3. Nephrotic Syndrome: Occurs in a minority of patients, usually associated with severe podocytopathy.
4. Hypertension: Often present at diagnosis, indicating significant renal involvement.
5. Acute Kidney Injury (AKI): May occur due to gross hematuria causing tubular obstruction by RBC casts or as a result of rapidly progressive crescentic glomerulonephritis.

5. Diagnostic Pathway and Differential Diagnosis

Key Diagnostic Tests

• Urinalysis: Essential for identifying hematuria, proteinuria, and dysmorphic RBCs or RBC casts.
• Serum Creatinine/eGFR: To assess baseline renal function.
• 24-hour Urine Collection/UPCR: To quantify the degree of proteinuria (a critical prognostic marker).
• Renal Biopsy: The definitive diagnostic tool, involving light microscopy, immunofluorescence (showing IgA dominance), and electron microscopy.

Differential Diagnosis

• Henoch-Schönlein Purpura (HSP): Systemic IgA vasculitis; essentially the systemic form of IgAN.
• Lupus Nephritis: Often shares immune complex deposition; distinguished by serology (ANA, dsDNA).
• Thin Basement Membrane Disease: Typically presents with hematuria but lacks mesangial proliferation.
• Post-infectious Glomerulonephritis: Typically presents with low complement levels (C3), unlike IgAN.

6. Risks, Complications, and Contraindications

Long-term Risks

• Chronic Kidney Disease (CKD): Progressive loss of filtration capacity.
• Cardiovascular Disease: Patients with IgAN have an increased risk of CV events due to hypertension and systemic inflammation.
• Renal Failure: Transition to ESRD requiring dialysis or transplantation.

Contraindications/Precautions

• NSAIDs: Should be strictly avoided or used with extreme caution, as they further reduce renal perfusion and exacerbate interstitial injury.
• ACE Inhibitors/ARBs: While these are the cornerstone of treatment, they must be monitored closely for hyperkalemia and acute rises in creatinine.

7. Management and Therapeutic Strategies

Management is stratified based on the risk of progression.

1. Supportive Care: The foundation for all patients. Includes blood pressure control (target <125/75 mmHg), RAAS inhibition (ACE inhibitors or ARBs), and SGLT2 inhibitors.
2. Immunosuppression: Reserved for high-risk patients (e.g., persistent proteinuria >1g/day despite supportive therapy). Options include corticosteroids, cyclophosphamide (for RPGN), or newer agents like mycophenolate mofetil.
3. Lifestyle Modifications: Smoking cessation, low-sodium diet, and weight management.

8. Frequently Asked Questions (FAQ)

1. Is IgA Nephropathy hereditary?
IgAN has a genetic predisposition, but it is not considered a classic Mendelian inherited disease. Family members have an increased risk, but routine screening is not universally recommended.

2. Can IgA Nephropathy be cured?
There is no "cure" that eliminates the underlying immune dysregulation. However, it can be managed effectively to achieve long-term remission and prevent or delay progression to ESRD.

3. What is the significance of the Oxford MEST-C score?
It provides a prognostic roadmap. Higher scores (particularly T1/T2 and S1) indicate a higher likelihood of progression to kidney failure, guiding the intensity of treatment.

4. Why does hematuria happen after a cold or sore throat?
The mucosal immune system (in the throat) is activated during an infection. In patients with IgAN, this leads to the overproduction of the pathogenic, galactose-deficient IgA1, which then deposits in the kidneys.

5. How often should I have my urine checked?
For stable patients, monitoring every 3–6 months is standard. Those with proteinuria or rising creatinine require more frequent assessment.

6. Is a kidney biopsy always required?
Not always. In patients with isolated microscopic hematuria and normal blood pressure/proteinuria, a biopsy may be deferred in favor of close observation.

7. Does diet play a role in managing IgAN?
While no specific "IgAN diet" exists, a low-sodium and protein-controlled diet can reduce the workload on the kidneys and help control hypertension.

8. Can I live a normal life with IgA Nephropathy?
Yes. Many patients with IgAN live normal life spans with stable renal function, provided they adhere to blood pressure control and regular monitoring.

9. What is the impact of pregnancy on IgAN?
Pregnancy can be safe, but it carries higher risks of preeclampsia and hypertension. It requires co-management between nephrology and high-risk obstetrics.

10. What is the recurrence rate after a kidney transplant?
Recurrence of IgA deposits in the transplanted kidney is common (up to 50%), but clinical graft failure due to recurrence is relatively low (approx. 10%).

9. Prognosis and Long-Term Outlook

The prognosis of IgA Nephropathy is variable. Patients with persistent proteinuria >1g/day, hypertension, and advanced MEST-C scores (specifically tubular atrophy and interstitial fibrosis) have the worst outcomes. Conversely, those with isolated hematuria and normal blood pressure often maintain stable renal function for decades.

Prognostic Indicators Table

Conclusion

IgA Nephropathy remains a complex, multifaceted disease requiring a personalized approach. By leveraging the Oxford Classification and emphasizing early, aggressive supportive care (specifically RAAS inhibition), clinicians can significantly improve patient outcomes. Ongoing research into complement pathway inhibitors and B-cell modulating therapies promises to further refine the therapeutic landscape in the coming decade.

Disclaimer: This guide is for educational and clinical reference purposes only. Clinical decisions should always be based on individual patient assessment, current institutional protocols, and peer-reviewed clinical trial data.